RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo attack on tough head & neck cancers
Disease control Not yet recruitingThis study aims to see if giving radiation therapy (either standard X-ray or proton therapy) along with an immunotherapy drug (pembrolizumab) before surgery is safe and more effective for people whose head and neck cancer has come back. The research will involve about 40 adults w…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Cincinnati • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Cancer clock: does morning or afternoon treatment work better?
Disease control Not yet recruitingThis study is testing whether the time of day a standard immunotherapy treatment is given affects how well it works for people with advanced solid tumors. Researchers want to see if a patient's internal body clock influences the treatment's effectiveness. About 160 participants w…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New combo attack on tough head & neck cancers
Disease control Not yet recruitingThis early-stage trial is testing whether a new drug called camonsertib, combined with a precise form of radiation therapy, can help control head and neck cancers that have returned or cannot be surgically removed. The main goals are to find the safest dose of the drug-radiation …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC